- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03829475
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI (ICON-2)
January 25, 2024 updated by: Jessica Ravikoff Allegretti, Brigham and Women's Hospital
A Randomized Controlled Trial to Compare the Effectiveness of Fecal Microbiota Transplantation (FMT) in Combination With Bezlotoxumab Compared to FMT and Placebo for the Prevention of CDI Recurrence in Patients With Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection
This is a randomized controlled trial to assess the clinical and microbiological impacts of FMT in combination with Bezlotoxumab (bezlo) compared to FMT in combination with placebo in patients with both inflammatory bowel disease (IBD) a and clostridium difficile infection (CDI).
The investigators will prospectively enroll up to 150 IBD-CDI patients from 4 tertiary care FMT referral centers.
Patients will be randomized 1:1 to either receive FMT in combination with Bezlo of FMT and a placebo infusion.
Donor stool from healthy donors will be obtained from OpenBiome.
OpenBiome is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use.
Patients will be enrolled and followed prospectively for 3 months post therapy.
Stool and blood samples as well as clinical data will be collected at baseline, week 1, 8 and 12.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jessica Allegretti
- Phone Number: 6177326389
- Email: jallegretti@bwh.harvard.edu
Study Contact Backup
- Name: Emma McClure
- Phone Number: 6175257322
- Email: elmcclure@bwh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults age 18 or greater
- History of ≥ 2 episodes of recurrent CDI. CDI is defined as the presence of diarrhea ( Bristol 6 or 7 for 48 hours and a confirmatory test for CDI). Preferred testing will be a two-step method using GDH/EIA toxin, though PCR will be accepted based on hospital availability with confirmation of the most recent episode occurring within the prior 3 months
- Confirmed diagnosis of IBD (ulcerative colitis, Crohn's disease or indeterminate colitis)
- Undergoing FMT via colonoscopy for CDI as part of standard medical care
Exclusion Criteria:
- Unable or unwilling to undergo a colonoscopy
- Inpatient status, though patients can be screened while inpatients, the must be outpatient for the planned colonoscopy.
- Anticipated immediate or upcoming surgery within 30 days
- Need for continued non-anti-CDI antibiotic therapy
- History of total proctocolectomy
- Female patients who are pregnant or breastfeeding or plan to become pregnant in the next 6 months.
- Patients who are unable to give informed consent
- Participation in a clinical trial in the preceding 30 days or simultaneously during this trial
- Severe food allergy (anaphylaxis or anaphylactoid-like reaction)
- Life expectancy < 6 months
- Unable to adhere to protocol requirements
- Patient who have received an FMT in the past year
- Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines that it will put the subject at greater risk from FMT
- Patient who is diagnosed with NYHA class 3 or 4 Heart Failure
- Lab value of WBC <3.0 x 103/mm3 , Platelets <100 x 103/mm3 , ALT or AST > 1.5 x institutional ULN
- EBV or CMV negative if a patient is severely immunosuppressed ( defined as 3 or more immunosuppressing agents)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FMT + Bezlo
Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
|
This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
Other Names:
FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
Other Names:
|
Placebo Comparator: FMT + Placebo
Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
|
FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
Other Names:
placebo is an infusion of normal saline.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clostridium difficile recurrence
Time Frame: 8 weeks
|
positive test for CDI by EIA toxin
|
8 weeks
|
Clostridium difficile recurrence
Time Frame: 8 weeks
|
Diarrhea defined at 3 or more bowel movements bristol 6-7 for 2 consecutive days
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diarrheal symptoms
Time Frame: 12 weeks
|
Number of Bowel movements daily
|
12 weeks
|
Rectal bleeding
Time Frame: 12 weeks
|
presence or absence of rectal bleeding
|
12 weeks
|
Abdominal Pain
Time Frame: 12 weeks
|
presence of absence of abominal pain
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2020
Primary Completion (Estimated)
February 1, 2024
Study Completion (Estimated)
March 1, 2024
Study Registration Dates
First Submitted
January 26, 2019
First Submitted That Met QC Criteria
February 1, 2019
First Posted (Actual)
February 4, 2019
Study Record Updates
Last Update Posted (Estimated)
January 26, 2024
Last Update Submitted That Met QC Criteria
January 25, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on Bezlotoxumab
-
David Binion, MDMerck Sharp & Dohme LLCRecruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | C. Diff. InfectionsUnited States
-
Michael E Villarreal, MDMerck Sharp & Dohme LLCTerminatedClostridia Difficile Colitis | Clostridium; SepsisUnited States
-
Fundacion SEIMC-GESIDAMerck Sharp & Dohme LLCCompletedClostridium Difficile InfectionSpain
-
The Cooper Health SystemUnknownClostridium Difficile Infection Recurrence
-
University of Illinois at ChicagoMerck Sharp & Dohme LLCCompletedClostridium Difficile Infection | Clostridium Difficile Infection RecurrenceUnited States
-
Montefiore Medical CenterMerck Sharp & Dohme LLCTerminatedClostridium DifficileUnited States
-
University of Kansas Medical CenterMerck Sharp & Dohme LLCCompletedClostridium Difficile Infection RecurrenceUnited States
-
Leiden University Medical CenterErasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaboratorsWithdrawnClostridium Infections | Enterocolitis, Pseudomembranous | Clostridioides DifficileNetherlands
-
Merck Sharp & Dohme LLCCompletedClostridium Difficile InfectionUnited States, Argentina, Brazil, Colombia, Czechia, Germany, Hungary, Malaysia, Mexico, Norway, Poland, Portugal, Romania, South Africa, Spain, Sweden, United Kingdom
-
Hellenic Institute for the Study of SepsisCompletedMortality | Clostridioides Difficile Infection | Organ Dysfunction Syndrome | Stool Microbiome | Clostridioides Difficile Infection RecurrenceGreece